Given age-related differences in drug metabolism and indications for hematopoietic SCT (HSCT), personalized drug dosing of the conditioning regimen and post-transplant immunosuppression may reduce graft rejection, relapse rates and toxicity in pediatric HSCT recipients. This manuscript summarizes the pharmacokinetic/dynamic data of HSCT conditioning and post-grafting immunosuppression, presented at the First Annual Pediatric Bone Marrow Transplant Consortium (PBMTC) meeting in April 2013. Personalized dosing of BU to a target plasma exposure reduces graft rejection in children and improves relapse/toxicity rates in adults. Current weight-based dosing achieves the target BU exposure in only a minority (24.3%) of children. The initial BU dose should be based on the European Medicines Agency nomogram or population pharmacokinetic models to improve the numbers of children achieving the target exposure. There are limited pharmacokinetic data for treosulfan, CY, fludarabine and alemtuzumab as HSCT conditioning in children. For post-grafting immunosuppression, mycophenolic acid (MPA) clearance may be increased in younger children (o 12 years). The preferred MPA pharmacokinetic monitoring parameters and target range are still evolving in HSCT recipients. Multi-institutional trials incorporating properly powered pharmacokinetic/dynamic studies are needed to assess the effect of variability in the plasma exposure of drugs/metabolites on clinical outcomes in pediatric HSCT recipients.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) has curative potential for patients with malignant or nonmalignant diseases. 1, 2 However, nonrelapse mortality and relapse continue to be problematic. 1, 2 Personalized dosing of the conditioning regimen and/or postgrafting immunosuppression may improve nonrelapse mortality and relapse rates. Personalized dosing of BU, CYA and tacrolimus using therapeutic drug monitoring (TDM) and dose modifications is well established and data support its use. Fewer data are available for other conditioning regimen agents and mycophenolate mofetil (MMF). TDM is costly and time consuming, therefore it should be conducted when it can meaningfully improve clinical outcomes.
Compared with adults, children often have greater pharmacokinetic variability and possibly altered pharmacodynamics. However, pharmacokinetic data in children are often sparse and robust trials to support TDM are often lagging behind those in adults. It is well known that children have age-related differences in drug metabolism, 3 which can potentially alter susceptibility to regimen-related toxicity and thus nonrelapse mortality, especially in the myeloablative setting. Concerns over the blood volume needed for pharmacokinetic and biomarker studies can limit enrollment of younger children. For example, measurement of fludarabine triphosphate (F-ara-ATP) formation in CD4 + and CD8 + cells requires 50 mL of blood for flow cytometry. 4 The pharmacodynamics may differ in pediatric recipients because of thymus-dependent regeneration of CD4+ and CD8+ after chemotherapy. 5, 6 Furthermore, engraftment kinetics after reduced intensity (RIC) conditioning differ between children and adults. 7 Infants and very young children are particularly difficult to treat as little is known about the pharmacokinetic disposition of common conditioning agents and immunosuppressants in this group. Even less is known about pharmacodynamics in children, especially in those with nonmalignant disease in whom the rarity of the diseases makes properly powered single-center trials unfeasible. Utilization of TDM of conditioning chemotherapy agents becomes especially important in these children, as newborn screening programs for primary immune deficiencies and inborn errors of metabolism available in some of the states, now allow HSCT to occur in early infancy. 8, 9 HSCT of infants carries a special set of challenges given the immaturity and delayed development of some of the organ systems involved in drug disposition.
TDM of post-grafting immune suppression has been the standard of care for decades, with well-established plasma trough concentration targets for calcineurin inhibitors. Over a decade ago, MMF was recognized as an alternative to MTX-based acute GVHD prophylaxis. Despite known target concentrations for mycophenolic acid (MPA) in solid organ transplant recipients, targets in HSCT are still under investigation primarily because of the large inter and intra-patient pharmacokinetic variability and lack of clarity on needed immunosuppressive intensity in the broad range of transplants in pediatrics (that is, malignant vs nonmalignant, related vs unrelated donor).
This manuscript reports on the data presented at the first annual PBMTC meeting in April 2013 and summarizes the 1 opportunities to improve outcomes for pediatric HSCT recipients using pharmacokinetics. Those readers who desire a comprehensive review of the pharmacokinetics of each medication are encouraged to read previous reviews or recent pharmacokinetic/ dynamic publications. [10] [11] [12] PHARMACOKINETICS/DYNAMICS OF THE CONDITIONING REGIMEN The primary goal of the conditioning regimen is to adequately ablate the recipient's hematopoietic cells to allow for donor cell engraftment and eradicate residual malignancy in those children with a cancer diagnosis. A summary of the differences in the pharmacokinetics and pharmacodynamics of HSCT conditioning regimens between children and adults is presented in Table 1 .
The alkylating agent BU is widely used in both high-dose and reduced intensity HSCT conditioning regimens 1, [13] [14] [15] [16] [17] and prior to gene therapy. [18] [19] [20] [21] [22] BU is the most common chemotherapy agent used in HSCT conditioning regimens that do not include TBI. Because the acute and long-term effects of TBI can be devastating, 23 it is vital to improve the efficacy and toxicity of BU. BU has a narrow therapeutic index, with data demonstrating that BU plasma exposure-expressed as concentration at steady state (Css) or area under the curve (AUC)-is a predictive biomarker that forecasts the likely response.
1,2,24 Therapeutic drug monitoring of BU, abbreviated targeted BU ( T BU), is typically conducted in children undergoing myeloablative conditioning.
One of the first considerations for BU-based conditioning is the administration route, frequency of administration and duration of therapy. Initially, only oral BU was available. Early pharmacokinetic/dynamic studies suggested that graft rejection was associated with low BU Css and that TDM of oral BU improved rejection rates. [25] [26] [27] I.v. BU was Food and Drug Administration approved in February 1999, which recommended TDM in children receiving BU/CY conditioning. 28 I.v. BU was rapidly adopted in pediatrics; 29 however, recent data demonstrate that targeted oral BU results in similar clinical outcomes to i.v. BU in children. 30 BU was initially administered q6h 25 because of the sole availability of a 2 mg oral tablet and the high initial (that is, before TDM) dose of 1 mg/kg. With the availability of i.v. BU, less frequent dosing schedules (for example, q24h) have gained popularity. Small case series in children suggest that daily i.v. BU administration is as safe as q6h administration, 13, [31] [32] [33] [34] with some centers even using q8h or q12h dosing. 35 The majority of HSCT conditioning regimens involve 4 days of BU therapy; 35 however, the increasing use of shorter i.v. BU courses 1, 13, 18, 21 necessitates alternative methods to personalize i.v. BU because of the time delay with TDM.
Weight-based dosing of i.v. BU results in only a minority (24.3%) of children obtaining their personalized target Css, 35 suggesting that alternative methods to estimate the initial BU dose are needed. BU clearance is associated with age and various body metrics (typically body weight) in the majority of population pharmacokinetic models of BU. 36 Similar to using the Calvert equation to estimate carboplatin clearance, 37 population pharmacokinetic models could be used to estimate a child's clearance and from this the initial i.v. BU dose to achieve a T BU Css. Seeking to develop a model generalizable over a wide-age spectrum, McCune and Holford et al. 36 recently developed an ageand size-dependent population pharmacokinetic model to predict i.v. BU doses in 1610 HSCT recipients (92% o 20 years old). I.v. BU clearance, scaled to body size, was predicted to be 95% of the adult clearance at 2.5 years postnatal age. Initial i.v. BU doses should be based on this age-and size-dependent model or the European Medicines Agency nomogram (Table 2) , 38 which had similar success achieving the target Css of 770 ng/mL (Table 3 ). In the future, this model could be integrated into a decision support system that includes relevant clinical data in a user-friendly interface to communicate the optimal initial and subsequent (that is, after pharmacokinetic results are available) BU doses.
Another important consideration with BU is choosing the patient-specific target Css. BU plasma exposure has been associated with rejection, relapse and toxicity in HSCT recipients conditioned with BU. There is substantive variability in the T BU Css for children with the same disease, 35 which has no clear rationale. The patient-specific target Css must be chosen carefully, considering that the target Css is influenced by the age, underlying disease and conditioning regimen. 39 Pharmacodynamic associations found in adults cannot be replicated in children. For example, no clear pharmacodynamic association exists between BU Css and hepatotoxicity in children receiving BU/melphalan or targeted BU/CY. [40] [41] [42] Similarly, no pharmacodynamic association exists between BU Css and relapse risk in children with AML from single institution studies. 40, 43 To better understand the clinical relevance of BU Css, a well-characterized repository including the other components of the conditioning regimen, the degree of myeloablation intended and the organ function could generate an adequate sample size to appropriately characterize BU pharmacodynamics in a homogenous population There are multiple case series describing the use of the alkylating agent treosulfan in pediatric HSCT recipients, which suggest acceptable outcomes. 44, 45 Treosulfan has similar pharmacokinetics between adults and a limited number of children (N = 7), 46 with an ongoing clinical trial of treosulfan pharmacokinetics in children. 47 Analytical methods, population pharmacokinetics and limited sampling strategy for treosulfan have recently been developed and validated in 20 pediatric allogeneic HSCT recipients. 48 However, larger studies are needed to evaluate the relationship between treosulfan exposure and post-transplant outcome in children.
The alkylating agent CY is used in pediatric HSCT, either in combination with TBI or targeted BU. The current method of dosing CY based on body surface area or weight leads to considerable interpatient variability in systemic exposure to CY and its metabolites, including 4-hydroxycyclophosphamide (4HCY), the precursor to CY's primary cytotoxic metabolite phosphoramide mustard. 49, 50 CY exhibits age-dependent pharmacokinetics, in which age affects the nonrenal clearance. 51, 52 In children, myeloablative dose CY leads to lower 4HCY formation than lower doses (that is, o 1000 mg/m 2 ). 53 The pharmacodynamics of CY and its metabolites have yet to be studied in pediatric HSCT, although the data in adults suggest conditioning regimen-dependent pharmacodynamics. 54 Future studies should focus upon building limited sampling schedules to characterize the pharmacokinetics of CY and its metabolites in children to allow for pharmacodynamics studies over the entire age spectrum.
The nucleoside inhibitor fludarabine is increasingly used for pediatric HSCT conditioning to lymphodeplete the recipient. After administration, fludarabine is quickly dephosphorylated to F-ara-A by nucleotidases.
55-57 F-ara-A subsequently undergoes uptake and sequential phosphorylation to its active metabolite, F-ara-ATP, which inhibits ribonucleotide reductase and DNA polymerase. 56 F-ara-A clearance is associated with body surface area in adults, 58 but no comprehensive studies have been conducted in pediatric HSCT. Similar to BU and CY, conditioning regimen-dependent pharmacodynamic relationships exist with plasma F-ara-A exposure.
59,60 F-ara-ATP accumulation in various cell subtypes (that is, CD4 + , CD8 + , peripheral blood mononuclear cells) may also be a predictive biomarker. 4 Further studies testing the hypothesis that interpatient variability of clinical outcomes is associated with biomarkers of fludarabine are necessary. No studies have evaluated for age-dependent pharmacokinetics or pharmacodynamics of fludarabine.
Alemtuzumab, which is a humanized igG-1 anti-CD52 monoclonal antibody, is also increasingly used for pediatric HSCT. 61, 62 Alemtuzumab is lymphotoxic at concentrations 4100 ng/mL. 63 When antigen concentration is high, half-life is short because the monoclonal antibody binds to its epitope and rapidly cleared. As the antigen is depleted, clearance decreases and half-life increases. 64, 65 There is substantive variability in the half-life of alemtuzumab (that is, 73 to 214 days). 66, 67 Age is not a factor in adult populations, 65 but the impact in children is unknown. More systematic studies using a phase I approach to developing novel alemtuzumab-based conditioning regimens should be conducted in children to identify the optimal dose and dosing schedule of alemtuzumab in this setting.
PHARMACOKINETICS/DYNAMICS OF MYCOPHENOLATE POST-GRAFTING IMMUNOSUPPRESSION
MMF is an ester prodrug of MPA, the active compound. It is a purine analog, which interferes with the de novo pathway of nucleotide synthesis through inhibition of inosine monophosphate dehydrogenase, thereby inhibiting T-and B-cell proliferation. In HSCT, MMF is primarily used as post-grafting immunosuppression following RIC regimens in combination with a calcineurin inhibitor where it promotes engraftment and contributes to GVHD protection.
The metabolism, distribution and transport of MMF is complex, which in part has led to difficulties in defining the optimal doses. MPA is glucuronidated by UDP glucuronosyl transferases primarily in the liver and kidneys, forming MPA glucuronide (inactive metabolite) and to a lesser extent acyl-MPA glucuronide (active metabolite) and 7-O-glucoside (inactive). Metabolites are excreted in the urine and bile and accumulate in renal dysfunction. MPA glucuronide and MPA present in the bile are subject to enterohepatic circulation (EHC), which is mediated through multidrug resistance-associated protein-2 transporters. Although up to 40% of the AUC may come from EHC, the amount undergoing EHC is lower in HSCT, especially if receiving CYA. 68 Oral bioavailability of MMF is generally high. However, in adult HSCT recipients it is substantially lower (56-72.3%) with high interpatient variability. [68] [69] [70] [71] Bioavailability has not been studied in pediatric HSCT recipients but similar variability is expected. Reasons for erratic bioavailability are multifactorial and may include the use of proton pump inhibitors that reduces oral MMF dissolution, 72 and the use of gut decontamination leading to reduced EHC. 73 CYA inhibits multidrug resistance-associated protein-2 transporters leading to impaired EHC and lowers Abbreviations: CNI = calcineurin inhibitor; CYA Pharmacokinetics in pediatric hematopoietic SCT JS McCune et al bioavailability compared with those receiving tacrolimus. 74, 75 In addition, tacrolimus is a potent inhibitor of UDP glucuronosyl transferases, thereby impairing MPA metabolism and increasing MPA concentrations. 76 Data suggest decreasing bioavailability with increasing MMF doses in a nonlinear manner. 77 Because of these problems, i.v. MMF should be used in children in the early post-transplant period and caution exercised when converting to oral therapy.
MPA and MPA glucuronide are 98-99% bound to albumin. As only unbound MPA has pharmacologic activity, changes in albumin may potentially alter activity or toxicity. Protein binding may be altered in renal or liver dysfunction and possibly by hypoalbuminemia. 68, 69, [78] [79] [80] Patients developing protein binding changes may have normal total MPA concentrations but high unbound concentrations. In this setting unbound concentrations are a better reflection of immunosuppressive activity.
Intra-and inter-patient pharmacokinetic variability is high in HSCT recipients and provides a significant therapeutic challenge. Selected pharmacokinetic data are provided in Table 4 . The pharmacokinetic variability of MPA has been associated with several factors, such as renal and hepatic function, weight, concomitant calcineurin inhibitor, CYA trough concentration, age and albumin, although the majority remain unknown. 68, 69, 78, 81 In a predominantly adult population of HSCT recipients, 68 more rapid total MPA clearance was associated with concomitant CYA use and lower serum albumin. Higher oral MMF doses are needed with concomitant CYA, which increases MPA clearance by 33.8%. 68 HSCT recipients have higher MPA clearance and often require higher oral MMF doses compared with solid organ transplant recipients, 82, 83 possibly due to the decreased EHC and concomitant CYA. Pediatric HSCT patients receiving MMF have higher MPA clearance rates compared with adults requiring higher and more frequent MMF dosing than the conventional 15 mg/kg q12h initially used by most centers. 84 Limited exposure-response data are available in HSCT. In adults receiving RIC-related and -unrelated HSCT with MMF 1 g q12h plus CYA, a higher cumulative incidence of engraftment was associated with total MPA troughs 41 mcg/mL (P o0.01). 83 An unbound MPA AUC 0-6 h 4150 or AUC 0-12 h 4300 ng/h/mL was associated with less grade 2-4 acute GVHD (68% vs 40%, P = 0.02 and 58% vs 35%, P = 0.05, respectively). Approximately 50% of the patients were below these target concentrations at MMF doses of 1 g q12h. In another study of adult unrelated donor RIC HSCT, total MPA troughs ⩾ 1 mcg/mL and C ss 42.96 mcg/mL were associated with better donor chimerism. 85 In a large study of adults undergoing RIC HSCT followed by MMF and CYA, total MPA pharmacokinetics were not associated with outcomes in related donor recipients. However, in patients receiving unrelated grafts a total MPA C ss o 3 mcg/mL was associated with more grades III-IV acute GVHD and more nonrelapse mortality. 86 Because data are lacking in children, centers performing TDM have adopted adult HSCT targets or targets used in pediatric solid organ transplant. These targets may not be directly applicable to children receiving cord blood or those with nonmalignant disease, where the necessary immunosuppression intensity may differ. Until properly powered pediatric studies are available, adult targets should be used. If monitoring unbound concentrations an AUC 0-8 h 200-250 ng/h/ mL for q8h dosing and if monitoring total concentrations total troughs ⩾ 1 mcg/mL or a total C ss 43 mcg/mL are reasonable targets. Unbound concentrations are especially important in patients with possible protein binding changes. In children and adults, MPA troughs are poorly correlated with AUC making TDM more difficult. 68, 84 Exposure may also be important when MMF is used for the treatment of acute GVHD. 87 Traditional doses of MMF 2 g/day in adult HSCT recipients achieve MPA exposures that are substantially lower compared with other populations. 82, 83 Adult doses of 3 g/day with CYA still do not achieve therapeutic plasma exposure in many patients. 88 Because of concerns about MPA-related hematologic and gastrointestinal toxicities, caution has been taken in continuing to escalate MMF doses. Dosing information in children is lacking. In young children, MMF 15 mg/kg q12h with CYA is insufficient. Although q8h dosing improves exposure, it does not consistently obtain MPA plasma exposure similar to adults. 84 Pediatric HSCT recipients receiving tacrolimus with MMF 900 mg/m 2 q8h achieve MPA plasma exposures similar to those of adults. 89 MPA clearance is higher in children o12 years. 89 Currently, the optimal dose in pediatric HSCT recipients is unclear. MMF doses of 15 mg/kg q8h or 600-900 mg/m 2 q8h are supported with pharmacokinetic literature, although these may not be sufficient for all children especially the very young. 84, 89 In children with hepatic or renal dysfunction dose reductions are necessary (that is, initially q12h but even more in severely compromised). Unbound concentrations are a more accurate reflection of exposure in critically ill children.
CONCLUSION
Despite improved understanding of the pharmacokinetics/pharmacodynamics of conditioning regimens and post-grafting immunosuppression in the past decade, pharmacokinetic and exposure-response data to support TDM still lag behind in children. Given that current dosing methods lead to the majority of children requiring BU dose adjustments after the initial dose, 24 the dosing or population pharmacokinetic models (Table 2) should be utilized to ensure that more children achieve their target Css in a shorter period of time. Future research should be multi-institutional and focus on developing clinical decision support systems to implement population pharmacokineticbased dosing of BU and study the pharmacodynamic relationship between BU Css, disease relapse and toxicity in homogenous populations. Additional studies are necessary to elucidate pharmacokinetic/dynamic relationship of CY, fludarabine and alemtuzumab in pediatric HSCT recipients.
MMF use has grown in HSCT. Pharmacokinetics of MPA has been extensively studied in adult HSCT recipients. MPA data are extremely limited in pediatric HSCT. The need for more frequent dosing in the early post-HSCT period has been shown; however, optimal pharmacokinetic parameters, target concentrations or duration of therapy have yet to be defined.
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